Logo image of RAPT

RAPT THERAPEUTICS INC (RAPT) Stock Fundamental Analysis

NASDAQ:RAPT - Nasdaq - US75382E1091 - Common Stock - Currency: USD

1.21  +0.1 (+9.01%)

After market: 1.23 +0.02 (+1.65%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RAPT. RAPT was compared to 572 industry peers in the Biotechnology industry. While RAPT seems to be doing ok healthwise, there are quite some concerns on its profitability. RAPT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RAPT had negative earnings in the past year.
RAPT had a negative operating cash flow in the past year.
RAPT had negative earnings in each of the past 5 years.
In the past 5 years RAPT always reported negative operating cash flow.
RAPT Yearly Net Income VS EBIT VS OCF VS FCFRAPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

RAPT's Return On Assets of -67.38% is on the low side compared to the rest of the industry. RAPT is outperformed by 64.42% of its industry peers.
With a Return On Equity value of -79.43%, RAPT perfoms like the industry average, outperforming 51.86% of the companies in the same industry.
Industry RankSector Rank
ROA -67.38%
ROE -79.43%
ROIC N/A
ROA(3y)-44.57%
ROA(5y)-45.8%
ROE(3y)-50.25%
ROE(5y)-52.07%
ROIC(3y)N/A
ROIC(5y)N/A
RAPT Yearly ROA, ROE, ROICRAPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

RAPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPT Yearly Profit, Operating, Gross MarginsRAPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

RAPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RAPT has more shares outstanding
RAPT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RAPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RAPT Yearly Shares OutstandingRAPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
RAPT Yearly Total Debt VS Total AssetsRAPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

RAPT has an Altman-Z score of -4.48. This is a bad value and indicates that RAPT is not financially healthy and even has some risk of bankruptcy.
RAPT has a Altman-Z score of -4.48. This is in the lower half of the industry: RAPT underperforms 60.18% of its industry peers.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.48
ROIC/WACCN/A
WACC10.7%
RAPT Yearly LT Debt VS Equity VS FCFRAPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 7.41 indicates that RAPT has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.41, RAPT is doing good in the industry, outperforming 69.91% of the companies in the same industry.
RAPT has a Quick Ratio of 7.41. This indicates that RAPT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.41, RAPT is doing good in the industry, outperforming 69.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.41
Quick Ratio 7.41
RAPT Yearly Current Assets VS Current LiabilitesRAPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

RAPT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.82%.
RAPT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)3.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.68%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RAPT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -12.24% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.5%
EPS Next 2Y28.62%
EPS Next 3Y17.87%
EPS Next 5Y-12.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPT Yearly Revenue VS EstimatesRAPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RAPT Yearly EPS VS EstimatesRAPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RAPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RAPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPT Price Earnings VS Forward Price EarningsRAPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPT Per share dataRAPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as RAPT's earnings are expected to grow with 17.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.62%
EPS Next 3Y17.87%

More info and screens

0

5. Dividend

5.1 Amount

RAPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RAPT THERAPEUTICS INC

NASDAQ:RAPT (2/5/2025, 8:23:28 PM)

After market: 1.23 +0.02 (+1.65%)

1.21

+0.1 (+9.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners92.11%
Inst Owner Change73.21%
Ins Owners1.9%
Ins Owner Change-683.59%
Market Cap42.30M
Analysts72.31
Price Target5.1 (321.49%)
Short Float %7.83%
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.97%
Min EPS beat(2)-6.73%
Max EPS beat(2)8.68%
EPS beat(4)2
Avg EPS beat(4)2.4%
Min EPS beat(4)-9.57%
Max EPS beat(4)17.22%
EPS beat(8)6
Avg EPS beat(8)5.09%
EPS beat(12)9
Avg EPS beat(12)4.54%
EPS beat(16)11
Avg EPS beat(16)3.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)66.67%
PT rev (3m)-37.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)8.21%
EPS NY rev (3m)10.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-2.77
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-2.81
FCFYN/A
OCF(TTM)-2.78
OCFYN/A
SpS0
BVpS4.21
TBVpS4.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.38%
ROE -79.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.57%
ROA(5y)-45.8%
ROE(3y)-50.25%
ROE(5y)-52.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 92.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.41
Quick Ratio 7.41
Altman-Z -4.48
F-Score2
WACC10.7%
ROIC/WACCN/A
Cap/Depr(3y)83.16%
Cap/Depr(5y)70.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.68%
EPS Next Y23.5%
EPS Next 2Y28.62%
EPS Next 3Y17.87%
EPS Next 5Y-12.24%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-48.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.8%
EBIT Next 3Y8.84%
EBIT Next 5YN/A
FCF growth 1Y-37.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.13%
OCF growth 3YN/A
OCF growth 5YN/A